MX2019003726A - Metodos para tratar fibroides uterinos y endometriosis. - Google Patents
Metodos para tratar fibroides uterinos y endometriosis.Info
- Publication number
- MX2019003726A MX2019003726A MX2019003726A MX2019003726A MX2019003726A MX 2019003726 A MX2019003726 A MX 2019003726A MX 2019003726 A MX2019003726 A MX 2019003726A MX 2019003726 A MX2019003726 A MX 2019003726A MX 2019003726 A MX2019003726 A MX 2019003726A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- methods
- endometriosis
- reducing
- uterine fibroids
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Surgical Instruments (AREA)
Abstract
Metodos para tratar fibroides uterinos, endometriosis, adenomiosis, o sangrado menstrual abundante en un sujeto, que incluyen administrar al sujeto entre 10 mg y 60 mg por dia de N-(4-(1-(2,6-difluorobencil)-5-((dimetilamino)metil)-3-(6-metoxi- 3-piridazinil)-2,4-dioxo- 1,2,3,4-tetrahidrotieno[2,3-d]pirimidin- 6-il)fenil)-N'-metoxiurea, y entre 0,01 mg y 5 mg por dia de un medicamento de reemplazo hormonal; la presente divulgacion tiene metodos para reducir el sangrado menstrual en un sujeto, reducir la perdida de densidad mineral osea en un sujeto causada por la administracion de un antagonista de GnRH al sujeto, suprimir las hormonas sexuales en un sujeto, reducir los sintomas vasomotores o sofocones de calor en un sujeto, y reducir los sintomas de disminucion de la libido en un sujeto que tiene fibroides uterinos, endometriosis, o adenomiosis; ademas se proveen metodos para mantener el perfil de glucosa sanguinea, mantener el perfil lipidico, y/o mantener la densidad mineral osea en una mujer premenopausica que se esta tratando para una o mas condiciones o sintomas de endometriosis, adenomiosis, fibroides uterinos, o sangrado menstrual abundante; y metodos para anticoncepcion y tratar la infertilidad.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402150P | 2016-09-30 | 2016-09-30 | |
| US201662402055P | 2016-09-30 | 2016-09-30 | |
| US201662402034P | 2016-09-30 | 2016-09-30 | |
| US201762492839P | 2017-05-01 | 2017-05-01 | |
| US201762528409P | 2017-07-03 | 2017-07-03 | |
| PCT/EP2017/074907 WO2018060501A2 (en) | 2016-09-30 | 2017-09-29 | Methods of treating uterine fibroids and endometriosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019003726A true MX2019003726A (es) | 2019-09-26 |
Family
ID=60915460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003726A MX2019003726A (es) | 2016-09-30 | 2017-09-29 | Metodos para tratar fibroides uterinos y endometriosis. |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US11033551B2 (es) |
| EP (2) | EP4094766B1 (es) |
| JP (1) | JP7043503B2 (es) |
| CN (1) | CN110312512B (es) |
| AU (2) | AU2017336363B2 (es) |
| BR (1) | BR112019006227A2 (es) |
| CA (1) | CA3038879A1 (es) |
| CY (1) | CY1125254T1 (es) |
| DK (1) | DK3518933T4 (es) |
| ES (2) | ES2912929T5 (es) |
| FI (1) | FI3518933T4 (es) |
| HR (1) | HRP20220708T4 (es) |
| HU (2) | HUE059101T2 (es) |
| IL (2) | IL265700B2 (es) |
| LT (1) | LT3518933T (es) |
| MD (1) | MD3518933T4 (es) |
| MX (1) | MX2019003726A (es) |
| NZ (1) | NZ752916A (es) |
| PL (2) | PL4094766T3 (es) |
| PT (1) | PT3518933T (es) |
| RS (1) | RS63300B2 (es) |
| SI (1) | SI3518933T2 (es) |
| SM (1) | SMT202200254T1 (es) |
| WO (1) | WO2018060501A2 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL308528A (en) | 2016-09-30 | 2024-01-01 | Takeda Pharmaceuticals Co | Treatment of prostate cancer |
| BR112019006227A2 (pt) | 2016-09-30 | 2019-06-18 | Myovant Sciences Gmbh | métodos de tratamento de leiomioma uterino e endometriose |
| WO2018224498A1 (en) | 2017-06-05 | 2018-12-13 | ObsEva S.A. | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| CA3066188A1 (en) | 2017-06-05 | 2018-12-13 | ObsEva S.A. | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| IL278082B2 (en) * | 2018-04-19 | 2025-03-01 | Abbvie Inc | Methods of treating heavy menstrual bleeding |
| CA3117092A1 (en) * | 2018-10-29 | 2020-05-07 | ObsEva S.A. | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis |
| RU2711658C1 (ru) * | 2019-04-16 | 2020-01-20 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" | Способ лечения наружного генитального эндометриоза |
| CN110194776B (zh) * | 2019-06-27 | 2021-05-28 | 四川伊诺达博医药科技有限公司 | 一种瑞卢戈利的合成方法 |
| EP4009977A2 (en) * | 2019-08-08 | 2022-06-15 | ObsEva S.A. | Compositions and methods for the treatment of estrogen-dependent disorders |
| CN115175912B (zh) * | 2019-10-10 | 2025-04-11 | 住友制药瑞士有限公司 | N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n′-甲氧基脲的结晶溶剂化形式 |
| WO2021069711A1 (en) * | 2019-10-10 | 2021-04-15 | Myovant Sciences Gmbh | Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea |
| AU2021224890A1 (en) * | 2020-02-19 | 2022-09-15 | Aspira Women's Health Inc. | Compositions for endometriosis assessment having improved specificity |
| CN113384581B (zh) * | 2020-03-12 | 2023-11-14 | 成都倍特药业股份有限公司 | 一种包含促性腺激素释放激素拮抗剂的药物组合物 |
| AR122175A1 (es) * | 2020-05-29 | 2022-08-24 | Myovant Sciences Gmbh | Formas de dosificación oral sólidas de combinación de antagonistas de la hormona liberadora de gonadotropina |
| JP2023549196A (ja) | 2020-11-11 | 2023-11-22 | ミオバント サイエンシズ ゲーエムベーハー | レルゴリクスの投与方法 |
| WO2023066941A1 (en) | 2021-10-18 | 2023-04-27 | Myovant Sciences Gmbh | Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| CN117069735A (zh) * | 2022-05-10 | 2023-11-17 | 北京海美源医药科技有限公司 | 一种高效合成瑞卢戈利的方法和其应用 |
| WO2024015934A2 (en) * | 2022-07-13 | 2024-01-18 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods of diagnostic screening and early detection of adenomyosis |
| TW202428262A (zh) * | 2022-11-09 | 2024-07-16 | 美商坦帕斯醫療公司 | 三唑酮化合物及其用途 |
| WO2025106820A1 (en) * | 2023-11-16 | 2025-05-22 | University Of South Florida | Method of preventing progesterone contraceptive-induced abnormal uterine bleeding (aub) |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US402034A (en) | 1889-04-23 | Dumping-wagon | ||
| US402150A (en) | 1889-04-30 | Broadcast seed-sower | ||
| US402055A (en) | 1889-04-23 | Water-motor | ||
| US492839A (en) | 1893-03-07 | Key for brake-shoes | ||
| US528409A (en) | 1894-10-30 | Denis ahern | ||
| FR2512732A1 (fr) | 1981-09-14 | 1983-03-18 | Raffinage Cie Francaise | Procede de fabrication d'objets composes d'un materiau rigide expanse a base de polychlorure de vinyle, objets obtenus par ce procede et leurs applications |
| US5340585A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
| ECSP961635A (es) | 1996-01-11 | 1997-06-27 | Desprendimiento controlado de esteroides del recubrimiento de azucar | |
| ECSP971998A (es) | 1997-01-15 | 1998-04-07 | Desprendimiento controlado de esteroides del recubrimiento de azucar | |
| DE19815060A1 (de) | 1998-04-03 | 1999-10-14 | Jenapharm Gmbh | Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie |
| US6265393B1 (en) * | 1998-08-07 | 2001-07-24 | Heinrichs William Leroy | Prevention of endometriosis signs or symptons |
| RU2233284C2 (ru) | 1999-03-24 | 2004-07-27 | Такеда Кемикал Индастриз, Лтд. | Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона |
| TWI225863B (en) | 1999-03-24 | 2005-01-01 | Takeda Chemical Industries Ltd | Thienopyrimidine compounds, their production and use |
| AU2001234188A1 (en) | 2000-02-29 | 2001-09-12 | Takeda Chemical Industries Ltd. | Processes for the production of thienopyrimidine derivatives |
| EP1479684A4 (en) | 2002-01-30 | 2006-01-04 | Takeda Pharmaceutical | THIENOPYRIMIDINES, METHODS OF MAKING AND USING SAME |
| AU2004207706B2 (en) | 2003-01-29 | 2010-03-04 | Takeda Pharmaceutical Company Limited | Thienopyrimidine compounds and use thereof |
| EP1646389B1 (en) | 2003-07-07 | 2008-09-10 | Neurocrine Biosciences, Inc. | Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists |
| MY151322A (en) | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
| EP1917978B1 (en) | 2005-07-22 | 2014-08-20 | Takeda Pharmaceutical Company Limited | Premature ovulation preventive agent |
| TWI386417B (zh) | 2005-12-22 | 2013-02-21 | Takeda Pharmaceutical | 轉移抑素衍生物及其用途 |
| ES2534573T3 (es) | 2007-04-06 | 2015-04-24 | Neurocrine Biosciences, Inc. | Antagonistas del receptor de la hormona liberadora de gonadotropina y métodos relacionados con los mismos |
| US8765948B2 (en) | 2007-11-07 | 2014-07-01 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
| WO2010026993A1 (ja) | 2008-09-03 | 2010-03-11 | 武田薬品工業株式会社 | 製剤における吸収性改善方法および吸収性が改善された製剤 |
| US9624161B2 (en) | 2009-02-23 | 2017-04-18 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
| US9427418B2 (en) | 2009-02-23 | 2016-08-30 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
| AU2011267798B2 (en) | 2010-06-16 | 2015-04-02 | Endorecherche, Inc. | Methods of treating or preventing estrogen-related diseases |
| JP2012077020A (ja) | 2010-09-30 | 2012-04-19 | Mochida Pharmaceut Co Ltd | ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬 |
| SMT202200255T1 (it) | 2012-09-28 | 2022-07-21 | Takeda Pharmaceuticals Co | Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea |
| EP3384930A1 (en) * | 2013-03-15 | 2018-10-10 | AbbVie Inc. | Compositions for use in treating heavy menstrual bleeding |
| EP4454708A3 (en) | 2015-02-26 | 2024-11-13 | Takeda Pharmaceutical Company Limited | A tablet comprising a methoxyurea derivative and mannitol particles |
| EP3344245A1 (en) | 2015-09-01 | 2018-07-11 | AbbVie Inc. | Methods of administering elagolix |
| IL308528A (en) | 2016-09-30 | 2024-01-01 | Takeda Pharmaceuticals Co | Treatment of prostate cancer |
| BR112019006227A2 (pt) | 2016-09-30 | 2019-06-18 | Myovant Sciences Gmbh | métodos de tratamento de leiomioma uterino e endometriose |
| WO2018224498A1 (en) | 2017-06-05 | 2018-12-13 | ObsEva S.A. | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| WO2021069711A1 (en) | 2019-10-10 | 2021-04-15 | Myovant Sciences Gmbh | Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea |
| CN115175912B (zh) | 2019-10-10 | 2025-04-11 | 住友制药瑞士有限公司 | N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n′-甲氧基脲的结晶溶剂化形式 |
| AR122175A1 (es) | 2020-05-29 | 2022-08-24 | Myovant Sciences Gmbh | Formas de dosificación oral sólidas de combinación de antagonistas de la hormona liberadora de gonadotropina |
| JP2023549196A (ja) | 2020-11-11 | 2023-11-22 | ミオバント サイエンシズ ゲーエムベーハー | レルゴリクスの投与方法 |
| WO2023066941A1 (en) | 2021-10-18 | 2023-04-27 | Myovant Sciences Gmbh | Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
-
2017
- 2017-09-29 BR BR112019006227-0A patent/BR112019006227A2/pt unknown
- 2017-09-29 SM SM20220254T patent/SMT202200254T1/it unknown
- 2017-09-29 CN CN201780072987.XA patent/CN110312512B/zh active Active
- 2017-09-29 HU HUE17823018A patent/HUE059101T2/hu unknown
- 2017-09-29 MX MX2019003726A patent/MX2019003726A/es unknown
- 2017-09-29 MD MDE20190880T patent/MD3518933T4/ro unknown
- 2017-09-29 RS RS20220565A patent/RS63300B2/sr unknown
- 2017-09-29 ES ES17823018T patent/ES2912929T5/es active Active
- 2017-09-29 AU AU2017336363A patent/AU2017336363B2/en active Active
- 2017-09-29 CA CA3038879A patent/CA3038879A1/en active Pending
- 2017-09-29 HR HRP20220708TT patent/HRP20220708T4/hr unknown
- 2017-09-29 HU HUE22162349A patent/HUE072130T2/hu unknown
- 2017-09-29 PL PL22162349.9T patent/PL4094766T3/pl unknown
- 2017-09-29 DK DK17823018.1T patent/DK3518933T4/da active
- 2017-09-29 PL PL17823018.1T patent/PL3518933T5/pl unknown
- 2017-09-29 ES ES22162349T patent/ES3018413T3/es active Active
- 2017-09-29 NZ NZ752916A patent/NZ752916A/en unknown
- 2017-09-29 EP EP22162349.9A patent/EP4094766B1/en active Active
- 2017-09-29 PT PT178230181T patent/PT3518933T/pt unknown
- 2017-09-29 EP EP17823018.1A patent/EP3518933B2/en active Active
- 2017-09-29 SI SI201731123T patent/SI3518933T2/sl unknown
- 2017-09-29 FI FIEP17823018.1T patent/FI3518933T4/fi active
- 2017-09-29 LT LTEPPCT/EP2017/074907T patent/LT3518933T/lt unknown
- 2017-09-29 JP JP2019538721A patent/JP7043503B2/ja active Active
- 2017-09-29 WO PCT/EP2017/074907 patent/WO2018060501A2/en not_active Ceased
-
2019
- 2019-03-28 IL IL265700A patent/IL265700B2/en unknown
- 2019-03-29 US US16/370,299 patent/US11033551B2/en active Active
-
2021
- 2021-05-11 US US17/317,769 patent/US11793812B2/en active Active
-
2022
- 2022-06-02 CY CY20221100390T patent/CY1125254T1/el unknown
- 2022-07-15 US US17/866,201 patent/US11957684B2/en active Active
- 2022-09-30 AU AU2022241582A patent/AU2022241582C1/en active Active
-
2023
- 2023-02-12 IL IL300580A patent/IL300580B2/en unknown
-
2024
- 2024-01-30 US US18/427,579 patent/US20240165118A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019003726A (es) | Metodos para tratar fibroides uterinos y endometriosis. | |
| Chen et al. | Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl) phenyl) amino) pyrimidin-2-yl) amino)-4-methoxy-2-(4-methyl-1, 4-diazepan-1-yl) phenyl) acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC | |
| MX2023001468A (es) | Tratamiento de cancer de prostata. | |
| NZ745957A (en) | Heterocyclic amides useful as protein modulators | |
| MX369576B (es) | Imidazoles 2-piridilo sustituidos como inhibidores de alk5 y/o alk4. | |
| NZ708563A (en) | Treatment of cancers using pi3 kinase isoform modulators | |
| EP4223298A3 (en) | Compositions for use in treating heavy menstrual bleeding | |
| MX2019009501A (es) | Compuestos de amino piridina utiles como inhibidores de ssao. | |
| JP2013540823A5 (es) | ||
| EA201791361A1 (ru) | Терапия антагонистом рецепторов окситоцина в лютеиновую фазу для имплантации и беременности у женщин, проходящих процедуры вспомогательных репродуктивных технологий | |
| BR112018075206A2 (pt) | tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida | |
| MX2019014482A (es) | Régimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para tratar miomas uterinos y reducir la menstruación. | |
| NZ757929A (en) | Benzoazepine analogs as inhibiting agents for bruton’s tyrosine kinase | |
| MX2015002005A (es) | Combinacion de inhibidor de p13k e inhibidor de c-met. | |
| NZ630828A (en) | Compounds and methods for treating aberrant adrenocartical cell disorders | |
| PE20210096A1 (es) | Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret | |
| MX2022013530A (es) | Combinación de terapia de células t dirigida a bcma y un compuesto inmunomodulador. | |
| PH12017502100A1 (en) | Selective progesterone receptor modulator (sprm) regimen | |
| EA201990857A1 (ru) | Способы лечения миомы матки и эндометриоза | |
| MY188267A (en) | Progesterone receptor antagonist dosage form | |
| MX389041B (es) | Regímenes de dosis de antagonista de oxitocina para promover la implantación embrionaria y prevenir abortos espontaneos. | |
| MA46362B1 (fr) | Méthodes de traitement des fibromes utérins et de l'endométriose | |
| EA201990762A1 (ru) | Способы лечения женского бесплодия | |
| EA201990057A1 (ru) | Схемы применения антагониста окситоцина для содействия имплантации эмбриона и предотвращения выкидыша | |
| HK1193045A1 (zh) | 在癌症如骨髓增殖性肿瘤治疗中的帕比司他与鲁索利替尼的组合 |